Moderna files application with FDA for updated COVID shot
Maddie Meyer

Moderna (NASDAQ:MRNA) has filed an application with the FDA seeking authorization of an updated COVID-19 shot focused against the XBB1.5 Omicron variant.
CEO Stephane Bancel said preliminary evidence indicates the updated jab is generates an immune response against several XBB variants of concern.

Earlier in June, the FDA advised pharmas that the vaccine intended to be given starting this fall should be a monovalent one against XBB1.5.
During a panel meeting of FDA advisors this month, a Pfizer (PFE) representative said his company could have the new shots ready by July.

More on Moderna

Moderna: Likely To Drop Further (Technical Analysis)
Moderna's Weakness Is Your Opportunity
Moderna: Don't Try To Catch The Falling Knives